Abstract

Spironolactone 5 mg/mL in SuspendIt Oral Suspension

Author(s): Allen Loyd V Jr

Issue: Nov/Dec 2017 - Volume 21, Number 6

Page(s): 496

Download in electronic PDF format for $75
  • Spironolactone 5 mg/mL in SuspendIt Oral Suspension Page 1

Abstract

A formulation for preparing Spironolactone 5 mg/mL in SuspendIt Oral Suspension. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • formulation
  • spironolactone
  • potassium-sparing diuretic
  • aldosterone antagonist
  • high blood pressure
  • hypertension
  • antihypertensive agent
  • congestive heart failure
  • fluid overload
  • fluid retention
  • edema
  • ascites
  • liver failure
  • hepatic disease

Related Categories

  • FORMULATIONS
  • GASTROENTEROLOGY
  • CARDIOLOGY
  • UROLOGY/URINARY TRACT

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Nov/Dec 2017
Pg. 496
Spironolactone 5 mg/mL in SuspendIt Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2018
Pg. 152
Spironolactone 5-mg/mL in Suspendit Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2017
Pg. 334-338
Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt
Author(s): Graves Richard, Phan Kelly V, Bostanian Levon A, Mandal Tarun K, Pramar Yashoda V
Sep/Oct 2021
Pg. 421
Spironolactone 2-mg/mL or 2-5.mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Sep/Oct 2018
Pg. 411
Torsemide 5 mg/mL in Ora-Plus:Ora-Sweet Suspension
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
May/Jun 2020
Pg. 238-241
Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions
Author(s): Wilder Alyson G, Foushee Jaime A, Fox Laura M, Navalle Jordan, Wright Adrienne M, Greer Megan A
Sep/Oct 2009
Pg. 367-371
Congestive Heart Failure and Other Medical Facts About Ferrets; Scout's Story: A Case Report on Treating Congestive Heart Failure in a Ferret
Author(s): Williams LaVonn A, Riley Kari
Nov/Dec 2004
Pg. 462-465
Basics of Compounding for Cough
Author(s): Allen Loyd V Jr
Jan/Feb 2021
Pg. 43
Amlodipine Besylate 0.5-mg/mL to 10-mg/mL in SuspendIt Oral Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2021
Pg. 503
Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
May/Jun 2006
Pg. 220
Carvedilol 1.25-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312
Wetting and/or Solubilizing Agents, Featured Excipient:
Author(s): Allen Loyd V Jr
Mar/Apr 2010
Pg. 157
Metolazone 10-mg/mL Injection
Author(s): Allen Loyd V Jr
Jan/Feb 2014
Pg. 61
Bumetanide 0.25-mg/mL Injection
Author(s): Allen Loyd V Jr
Jul/Aug 2014
Pg. 326
Chlorothiazide 50-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2019
Pg. 148
Captopril 0.8 mg/mL in SyrSpend SF Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2023
Pg. 326
Losartan Potassium 2.5-mg/mL Oral Liquid
Author(s): Allen Loyd V Jr
Jan/Feb 2022
Pg. 56
Enalapril Maleate 1 mg-mL in Ora-Plus and Ora-Sweet Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2022
Pg. 321-322
Furosemide 5-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr